GammaTile

GT Medical Technologies is a medical device company that developed GammaTile Therapy, an FDA-cleared Surgically Targeted Radiation Therapy (STaRT) for patients with intracranial neoplasms. The technology consists of a bioresorbable collagen tile embedded with Cesium-131 seeds, which is placed at the site of tumor resection to provide immediate, localized radiation. This approach aims to eliminate residual tumor cells while minimizing damage to healthy brain tissue and reducing the burden of traditional external beam radiation. The company focuses on improving clinical outcomes and quality of life for patients with glioblastomas, meningiomas, and brain metastases. GammaTile is designed to be implanted in minutes during the last stage of surgery, allowing radiation treatment to begin immediately.